01Ensysce Biosciences reported Q2 2026 earnings per share of -$0.20, beating the consensus estimate of -$0.50 by $0.30, and revenue of $1.2M exceeded the estimate of $994.0K.
02The company's stock trades at $0.35 with a market capitalization of $3.4M as of the earnings report date.
03The 60% earnings beat represents a notable deviation from consensus estimates and follows a pattern of recent outperformance, with Q1 beating by 28.8% and Q4 by 40.5%, though Q3 2025 missed by 46.2%.
04The company remains unprofitable with negative earnings per share, and investors should evaluate whether recent results reflect business acceleration or stabilization by comparing against year-over-year and sequential performance trends.
Earnings Results
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly earnings results on August 13, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.20, beating the consensus estimate of $-0.50 by $0.30 per share. Revenue came in at $1.2M, beating the estimate of $994.0K.
Company Overview
Ensysce Biosciences's stock moved following the earnings release. The stock currently trades at $0.35 with a market capitalization of $3.4M.
Ensysce Biosciences's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 60% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Ensysce Biosciences should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.